# Safety and Immunogenicity of Meningococcal Conjugate Vaccine in Healthy Adults Aged 19 to 55 Years Old

> **NCT04714229** · PHASE1 · COMPLETED · sponsor: **EuBiologics Co.,Ltd** · enrollment: 60 (actual)

## Conditions studied

- Infection, Meningococcal

## Interventions

- **BIOLOGICAL:** Meningococcal(Groups A, C, W-135, and Y) Conjugate Vaccine
- **BIOLOGICAL:** Meningococcal(Groups A, C, Y, and W-135) Conjugate Vaccine

## Key facts

- **NCT ID:** NCT04714229
- **Lead sponsor:** EuBiologics Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-01
- **Primary completion:** 2020-11-01
- **Final completion:** 2021-09-01
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2021-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04714229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04714229, "Safety and Immunogenicity of Meningococcal Conjugate Vaccine in Healthy Adults Aged 19 to 55 Years Old". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04714229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*